V
The FDA’s peptide circus is underway.
An advisory panel, stacked with RFK Jr.’s pro-peptide appointees, has voted to add BPC-157 and KPV to the bulk compounding list. This is despite FDA staff clinicians stating that there’s no convincing evidence. Central to the argument is whether allowing compounding will curtail the gray market or expose the public to unnecessary risk. Internally screaming.
Follow topics and authors from this story to see more like this in your personalized homepage feed and to receive email updates.
Loading comments
Getting the conversation ready...
Most Popular
Most Popular
- It’s not just LG. Every TV company is spying on you
- OpenAI and Microsoft knew they were starting a ‘doom loop’ for the web
- The 2.5-hour AI-generated Odyssey movie is 2.5 hours too long
- Gemini went rogue, hacked three companies, and Google hid it
- The Apple Watch Series 12 is the start of a new wearable era
